Clinical Trial Update: A Study to Evaluate IGSC 20% Biweekly Dosing in Treatment-Experienced Participants and Loading/Maintenance Dosing in Treatment-Naïve Participants With Primary Immunodeficiency [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating IGSC 20% biweekly dosing in treatment-experienced and loading/maintenance dosing in treatment-naïve participants with primary immunodef…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immunodeficiency

Drugs mentioned

• IGSC 20% (immunoglobulin G 20%)

Snippet

Sponsor: Grifols Therapeutics LLC | Conditions: Primary Immunodeficiency | Phase 4 | Status: COMPLETED | Results posted: 2023-08-07